QOL of Multiple Myeloma Patients Receiving Maintenance Therapy
This interview examines a study that looked at the health-related quality of life of multiple myeloma patients in a real-world setting who underwent maintenance therapy after autologous stem cell transplant.
In this interview, Rafat Abonour, MD, of the Indiana University Simon Cancer Center, discusses a study that examined the health-related quality of life of multiple myeloma patients who received maintenance therapy in a real-world setting.
Patients in the study (abstract 537) were part of the Connect MM registry. Patients had newly diagnosed disease, and the researchers compared those who received maintenance therapy (a majority with lenalidomide) after autologous stem cell transplant with those who did not.
Dr. Abonour presented results of the trial at the 58th Annual Meeting of the American Society of Hematology (ASH), held December 3–6 in San Diego, California.
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
